A new trading day began on Friday, with Verve Therapeutics Inc (NASDAQ: VERV) stock price up 4.37% from the previous day of trading, before settling in for the closing price of $5.72. VERV’s price has ranged from $4.30 to $20.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 126.44%. Meanwhile, its annual earnings per share averaged 17.45%. With a float of $62.47 million, this company’s outstanding shares have now reached $81.97 million.
Let’s determine the extent of company efficiency that accounts for 255 employees. In terms of profitability, gross margin is 61.18%, operating margin of -1075.0%, and the pretax margin is -931.71%.
Verve Therapeutics Inc (VERV) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 26.18%, while institutional ownership is 70.12%. The most recent insider transaction that took place on May 14 ’24, was worth 475,760. In this transaction an insider of this company bought 76,000 shares at a rate of $6.26, taking the stock ownership to the 342,509 shares. Before that another transaction happened on Apr 02 ’24, when Company’s Chief Administrative Officer sold 1,514 for $8.24, making the entire transaction worth $12,475. This insider now owns 8,659 shares in total.
Verve Therapeutics Inc (VERV) Recent Fiscal highlights
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.72 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.72 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.45% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Here are Verve Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.60, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.87 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Looking closely at Verve Therapeutics Inc (NASDAQ: VERV), its last 5-days average volume was 0.94 million, which is a drop from its year-to-date volume of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 81.59%. Additionally, its Average True Range was 0.36.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 45.55%, which indicates a significant decrease from 92.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.95% in the past 14 days, which was lower than the 72.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.30, while its 200-day Moving Average is $7.90. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $6.13. Second resistance stands at $6.30. The third major resistance level sits at $6.51. If the price goes on to break the first support level at $5.76, it is likely to go to the next support level at $5.56. Now, if the price goes above the second support level, the third support stands at $5.39.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
With a market capitalization of 505.18 million, the company has a total of 83,965K Shares Outstanding. Currently, annual sales are 11,760 K while annual income is -200,070 K. The company’s previous quarter sales were 6,690 K while its latest quarter income was -49,810 K.
